You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

CLINICAL TRIALS PROFILE FOR ETHOSUXIMIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ethosuximide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00088452 ↗ Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 3 2004-07-01 The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.
NCT00088452 ↗ Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study Completed Children's Hospital Medical Center, Cincinnati Phase 3 2004-07-01 The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.
NCT00689585 ↗ Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS) Terminated McGill University Phase 2 2008-09-01 Pain remains the most debilitating symptom for adult patients suffering from complex regional pain syndrome (CRPS). Most CRPS patients gain little to no relief from current painkillers. The purpose of this study is to evaluate the efficacy and safety of ethosuximide in search of much-needed adjunctive therapy to relieve the pain and suffering associated with CRPS.
NCT00689585 ↗ Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS) Terminated McGill University Health Center Phase 2 2008-09-01 Pain remains the most debilitating symptom for adult patients suffering from complex regional pain syndrome (CRPS). Most CRPS patients gain little to no relief from current painkillers. The purpose of this study is to evaluate the efficacy and safety of ethosuximide in search of much-needed adjunctive therapy to relieve the pain and suffering associated with CRPS.
NCT00689585 ↗ Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS) Terminated McGill University Health Centre/Research Institute of the McGill University Health Centre Phase 2 2008-09-01 Pain remains the most debilitating symptom for adult patients suffering from complex regional pain syndrome (CRPS). Most CRPS patients gain little to no relief from current painkillers. The purpose of this study is to evaluate the efficacy and safety of ethosuximide in search of much-needed adjunctive therapy to relieve the pain and suffering associated with CRPS.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ethosuximide

Condition Name

Condition Name for Ethosuximide
Intervention Trials
Peripheral Neuropathic Pain 2
Epilepsy 2
Cancer 1
Neuropathic Traumatic Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ethosuximide
Intervention Trials
Epilepsy 4
Syndrome 3
Epilepsy, Absence 2
Irritable Bowel Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ethosuximide

Trials by Country

Trials by Country for Ethosuximide
Location Trials
United States 24
France 4
United Kingdom 3
Egypt 2
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ethosuximide
Location Trials
Pennsylvania 2
Connecticut 1
Colorado 1
California 1
Arkansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ethosuximide

Clinical Trial Phase

Clinical Trial Phase for Ethosuximide
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ethosuximide
Clinical Trial Phase Trials
Recruiting 4
Unknown status 3
Completed 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ethosuximide

Sponsor Name

Sponsor Name for Ethosuximide
Sponsor Trials
University Hospital, Clermont-Ferrand 3
Imperial College London 1
Guy's and St Thomas' NHS Foundation Trust 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ethosuximide
Sponsor Trials
Other 35
U.S. Fed 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ethosuximide: Clinical Trials, Market Analysis, and Projections

Introduction to Ethosuximide

Ethosuximide is a potent anticonvulsant drug, primarily used to treat absence seizures in both adults and children. It belongs to the class of drugs known as succinimides and has been a cornerstone in the management of epilepsy for several decades.

Clinical Trials Update

Chemotherapy-Induced Peripheral Neuropathy Trial

One notable clinical trial involving ethosuximide was a randomized double-blind placebo-controlled study aimed at evaluating its safety and efficacy in managing chemotherapy-induced painful peripheral neuropathy. Here are the key points from this trial:

  • Trial Objectives: The main objective was to assess the reduction in average pain intensity from baseline to the end-point, measured on a 0-10 numerical rating scale[1].
  • Trial Status: The trial was terminated early due to low recruitment, with only 15 of the required 44 patients enrolled. None of the participants in the ethosuximide arm reached the week 6 evaluation point, resulting in no data for analysis[1].
  • Adverse Events: Adverse events were collected systematically from the point of randomization until 3 months after the last dose of the investigational medicinal product (IMP)[1].

This trial highlights the challenges in conducting clinical research, particularly when patient recruitment falls short of expectations.

Market Analysis

Global Market Size and Growth

The global ethosuximide market is experiencing significant growth driven by several key factors:

  • Market Size: As of 2025, the global ethosuximide market was valued at USD 403 million and is projected to grow to USD 631 million by 2033, exhibiting a Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period[2].
  • Market Drivers: The increasing prevalence of epilepsy worldwide, rising awareness of ethosuximide's efficacy and safety, and advances in research and development are major drivers of market growth[2][3].

Dominating Regions and Segments

  • Geographical Dominance: North America is expected to dominate the global ethosuximide market, driven by the high prevalence of epilepsy and advanced healthcare infrastructure[2].
  • Segment Dominance: Hospitals are expected to maintain a dominant share in the application segment due to the need for specialized epilepsy care. Capsules are projected to hold a larger share in the type segment due to their convenience and ease of administration[2].

Product Insights

Ethosuximide is widely recognized for its effectiveness in treating absence seizures. Here are some key product insights:

  • Therapeutic Use: Ethosuximide is considered the first-choice drug for treating absence seizures in both adults and children[5].
  • Formulations: The market is seeing the development of new formulations, such as extended-release or oral-dispersible forms, which are expected to augment market demand[3].

Market Trends

Generic Ethosuximide

The rising availability and acceptance of generic versions of ethosuximide are a significant market trend:

  • Generic Approvals: For example, Ethosuximide Softgel Capsules USP, 250 mg, developed by Strides Pharma Global, was approved by the FDA as a generic equivalent of Pfizer’s Zarontin (250 mg) Capsules. This increased generic penetration is expected to offer cost-effective treatment options, aiding in market expansion[3].

Government and Healthcare Initiatives

Government and healthcare initiatives are also playing a crucial role in boosting the market:

  • Supportive Policies: Policies and programs implemented by governments to promote epilepsy treatment and make medications more accessible and affordable are projected to boost the market size[3].

Focus on Pediatric and Adolescent Epilepsy

There is a growing focus on developing specialized treatments for pediatric and adolescent epilepsy patients:

  • Specialized Formulations: The development of formulations such as liquid or dissolvable forms of ethosuximide is aimed at providing accurate and flexible dosing for younger patients[3].

Precision Dosing and Clinical Studies

Recent studies have provided important insights into the precision dosing of ethosuximide:

  • Absence Epilepsy Study Group: A study involving quantitative pharmacology models described the pharmacokinetics and exposure-seizure-free response to inform precision dosing for initial ethosuximide monotherapy. The study found that 84 out of 103 participants achieved seizure freedom within a wide range of ethosuximide exposure[4].

Market Projections

Forecasted Market Size

The global ethosuximide market is projected to grow significantly over the next few years:

  • Forecasted Size: By 2033, the market is expected to reach USD 631 million, growing at a CAGR of 4.8% from 2025 to 2033[2].
  • Regional Growth: North America is expected to continue its dominance, while other regions such as Europe and Asia-Pacific are also anticipated to show substantial growth[2][5].

Competitive Landscape

The market is characterized by a competitive landscape with several key players:

  • Major Manufacturers: Companies such as Akorn, Bionpharma, Heritage Pharms, Parke Davis, Puracap Pharm, Strides Pharma, Banner Pharmacaps, Covenant Pharma, and Mikart are among the major stakeholders in the global ethosuximide market[5].

Key Takeaways

  • Ethosuximide remains a crucial drug in the treatment of absence seizures.
  • The global market is driven by increasing epilepsy prevalence, advances in research, and growing awareness of the drug's efficacy.
  • North America dominates the market due to advanced healthcare infrastructure.
  • Generic versions and new formulations are expected to boost market growth.
  • Precision dosing studies are enhancing the therapeutic use of ethosuximide.

FAQs

What is the primary use of ethosuximide?

Ethosuximide is primarily used to treat absence seizures in both adults and children.

What was the outcome of the clinical trial on ethosuximide for chemotherapy-induced peripheral neuropathy?

The trial was terminated early due to low recruitment, and no statistical analyses could be performed because none of the participants in the ethosuximide arm reached the week 6 evaluation point.

What are the key drivers of the global ethosuximide market growth?

The key drivers include the increasing prevalence of epilepsy worldwide, rising awareness of ethosuximide's efficacy and safety, and advances in research and development.

Which region is expected to dominate the global ethosuximide market?

North America is expected to dominate the global ethosuximide market due to the high prevalence of epilepsy and advanced healthcare infrastructure.

What are the emerging trends in the ethosuximide market?

Emerging trends include the rising availability of generic versions, increased focus on pediatric and adolescent epilepsy, and advances in research leading to new formulations and drug combinations.

Sources

  1. EudraCT Number 2008-004499-38 - Clinical trial results. Retrieved from Clinical Trials Register.
  2. Ethosuximide Market's Growth Catalysts - Data Insights Market. Retrieved from Data Insights Market.
  3. Ethosuximide Market Size, Share, Trends 2024-2032. Retrieved from Expert Market Research.
  4. Absence Epilepsy Study Group Provides Dosing Guidance for Ethosuximide. Retrieved from Cincinnati Children's Blog.
  5. Global Ethosuximide Market Insights, Forecast to 2030 - QYResearch. Retrieved from QYResearch.
Last updated: 2025-01-08

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.